These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 19300586)

  • 1. Progress update: Pharmacological treatment of Alzheimer's disease.
    Hogan DB
    Neuropsychiatr Dis Treat; 2007; 3(5):569-78. PubMed ID: 19300586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis.
    Thancharoen O; Limwattananon C; Waleekhachonloet O; Rattanachotphanit T; Limwattananon P; Limpawattana P
    Drugs Aging; 2019 May; 36(5):435-452. PubMed ID: 30937879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapy of Alzheimer's disease: an overview of systematic reviews.
    Majidazar R; Rezazadeh-Gavgani E; Sadigh-Eteghad S; Naseri A
    Eur J Clin Pharmacol; 2022 Oct; 78(10):1567-1587. PubMed ID: 35881170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
    Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
    Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology.
    O'Brien JT; Holmes C; Jones M; Jones R; Livingston G; McKeith I; Mittler P; Passmore P; Ritchie C; Robinson L; Sampson EL; Taylor JP; Thomas A; Burns A
    J Psychopharmacol; 2017 Feb; 31(2):147-168. PubMed ID: 28103749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis.
    Battle CE; Abdul-Rahim AH; Shenkin SD; Hewitt J; Quinn TJ
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013306. PubMed ID: 33704781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials?
    Ehret MJ; Chamberlin KW
    Clin Ther; 2015 Aug; 37(8):1604-16. PubMed ID: 26122885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
    Loveman E; Green C; Kirby J; Takeda A; Picot J; Payne E; Clegg A
    Health Technol Assess; 2006 Jan; 10(1):iii-iv, ix-xi, 1-160. PubMed ID: 16409879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
    Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
    Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer's disease.
    Haake A; Nguyen K; Friedman L; Chakkamparambil B; Grossberg GT
    Expert Opin Drug Saf; 2020 Feb; 19(2):147-157. PubMed ID: 31976781
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
    Tan CC; Yu JT; Wang HF; Tan MS; Meng XF; Wang C; Jiang T; Zhu XC; Tan L
    J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence-based pharmacotherapy of Alzheimer's disease.
    Evans JG; Wilcock G; Birks J
    Int J Neuropsychopharmacol; 2004 Sep; 7(3):351-69. PubMed ID: 15228642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-cholinergic strategies for treating and preventing Alzheimer's disease.
    Doraiswamy PM
    CNS Drugs; 2002; 16(12):811-24. PubMed ID: 12421115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.
    Nordberg A; Svensson AL
    Drug Saf; 1998 Dec; 19(6):465-80. PubMed ID: 9880090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Anti-Dementia Drugs (Anti-Alzheimer's Disease Drugs)].
    Yamada M
    Brain Nerve; 2023 May; 75(5):464-469. PubMed ID: 37194514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
    Cumbo E; Ligori LD
    J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Alzheimer's disease in the long-term-care setting.
    Smith DA
    Am J Health Syst Pharm; 2009 May; 66(10):899-907. PubMed ID: 19420308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholinesterase as a Target for Drug Development in Alzheimer's Disease.
    Sharma P; Tripathi MK; Shrivastava SK
    Methods Mol Biol; 2020; 2089():257-286. PubMed ID: 31773661
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.